Grant: Alliance Grants
Simon Fraser University
$58,632.00
Chemical biology probes to monitor glucocerebrosidase activity in fixed cells and tissues
EF 2021-22
Résumé
People generally have two copies of each gene. A mutation in one of the many disease-related genes that humans have can increase the risk of developing disease. But having a mutation in one of these disease-related genes does not always mean that a person will get the disease. Such a case is known to occur in Parkinson Disease (PD) where the most common hereditary factor contributing to PD are mutations in the gene called GBA. This gene codes for the protein glucocerebrosidase (GCase) that cuts glucose off from a sugar-modified fat molecule that is especially abundant in brain. Even though people with this mutation are much more likely to get PD earlier on and have more severe symptoms, not all people who have a mutation in the GBA gene do develop PD. This has led people to hypothesize that there are other genes that interact with GBA and either increase or decrease the chance of getting PD. This is known to occur for other diseases where mutations in various genes can influence the likelihood of developing a specific disease through what is known as a genetic interaction. There is accordingly high interest in identifying genes that interact with GBA and then understanding how they might influence GCase function. Indeed, little is known about how GCase is regulated within cells but such fundamental information could help better understand the regulation of this protein. In this proposal we aim to exploit our recent advances in chemical biology tools that enable directly watching the activity of GCase protein in living cells. In addition, we will chemically synthesize new probe molecules that enable measuring the activity of this enzyme in new ways. Ultimately, we will use these chemical tools to identify genes that interact with GBA using state of the art screening methods. In this way we will get a basic understanding of how such genes could regulate GCase. Such knowledge could be exploited by pharmaceutical companies to create new drugs that could benefit PD patients in Canada and around the world. Because PD is the second most common neurodegenerative disease, and there is no treatment that slows progression of PD, there is a great need to new insights that could be exploited to create new medicines.
Programme
Alliance Grants
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
558261-2020
Name nom
Vocadlo, David
Department département
Chemistry
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2020
Award amount
58632
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
3702
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Carbohydrates
Research subject fr
Glucides
Installment
inst:2
Partie
1
Nb partie
2
Application title
Chemical biology probes to monitor glucocerebrosidase activity in fixed cells and tissues
Keyword
NSERC
Application summary
People generally have two copies of each gene. A mutation in one of the many disease-related genes that humans have can increase the risk of developing disease. But having a mutation in one of these disease-related genes does not always mean that a person will get the disease. Such a case is known to occur in Parkinson Disease (PD) where the most common hereditary factor contributing to PD are mutations in the gene called GBA. This gene codes for the protein glucocerebrosidase (GCase) that cuts glucose off from a sugar-modified fat molecule that is especially abundant in brain. Even though people with this mutation are much more likely to get PD earlier on and have more severe symptoms, not all people who have a mutation in the GBA gene do develop PD. This has led people to hypothesize that there are other genes that interact with GBA and either increase or decrease the chance of getting PD. This is known to occur for other diseases where mutations in various genes can influence the likelihood of developing a specific disease through what is known as a genetic interaction. There is accordingly high interest in identifying genes that interact with GBA and then understanding how they might influence GCase function. Indeed, little is known about how GCase is regulated within cells but such fundamental information could help better understand the regulation of this protein. In this proposal we aim to exploit our recent advances in chemical biology tools that enable directly watching the activity of GCase protein in living cells. In addition, we will chemically synthesize new probe molecules that enable measuring the activity of this enzyme in new ways. Ultimately, we will use these chemical tools to identify genes that interact with GBA using state of the art screening methods. In this way we will get a basic understanding of how such genes could regulate GCase. Such knowledge could be exploited by pharmaceutical companies to create new drugs that could benefit PD patients in Canada and around the world. Because PD is the second most common neurodegenerative disease, and there is no treatment that slows progression of PD, there is a great need to new insights that could be exploited to create new medicines.